
Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care



Huma acquires AstraZeneca's digital health platform AMAZE™ and AstraZeneca becomes a shareholder of Huma

Huma announced a new partnership with AstraZeneca to scale innovation for digital health. This agreement follows prior use cases executed between Huma and AstraZeneca, reflecting a shared ambition to improve clinical outcomes through digital health solutions to bridge the gap between patients and clinicians.

As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate adoption of decentralized clinical trials. These will build on Huma's proven technologies which already power digital-first care serving more than 1.8 million active patient users across more than 3,000 hospitals and clinics. Huma's technologies are designed to connect with clinical workflows, allowing for more efficient care delivery.

"Our track record of scaling innovation has set the stage for this important partnership with one of the world's largest biopharmaceutical companies. I am excited to have AstraZeneca's support to build upon our 10-year experience of delivering digital-first solutions across healthcare and clinical trials," said Dan Vahdat, CEO of Huma. "The combination of pioneering leadership, global-reach, deep medical knowledge and digital innovation will enable our award-winning¹ platform to help more people live longer, fuller lives."

"This collaboration marks an important moment as it is a first for AstraZeneca in the digital health space as well as in the industry for chronic diseases and SaMDs in support of different treatments," said Karan Arora, Chief Commercial Digital Officer, AstraZeneca. "With Huma, we are accelerating AstraZeneca's ambition to achieve earlier diagnosis and treatment for patients with chronic diseases so they can lead better, more fulfilling lives."

Ninety-five percent of care for chronic conditions happens outside the clinical setting², highlighting the need for more digital-first care. AstraZeneca has invested in the development and clinical validation of the patient centered AMAZETM chronic disease management platform to improve the care of patients. AstraZeneca has used the AMAZETM platform to conduct clinical studies at leading U.S. academic medical centers with the goals of improving patient engagement, care-team communication and clinical outcomes while reducing healthcare costs. The collaboration with Huma will leverage the strong foundations and early success of AMAZETM to accelerate digital-first care across therapeutic areas and launch SaMDs.

"We are very excited to be working more closely with Huma across our digital health initiatives," said Ruud Dobber, Executive Vice President and President, Biopharmaceuticals Business Unit, AstraZeneca. "We believe digital can expand access to healthcare, advance clinical research, and identify existing gaps in care. Additionally, with this innovative partnership, we will bring a combination of technology along with expertise in research and drug development to global decentralized clinical trials advancing the science of right patient, right therapy, right time."

Source: [Huma Therapeutics](#)

References:

1. Huma Therapeutics [wins Prix Galien USA 2021](#) award for Best Digital Health Product
2. American Academy of Family Physicians: <https://www.aafp.org/fpm/2000/0300/p47.html>
3. NHSX report: <https://www.nhs.uk/covid-19-response/technology-nhs/huma-medopad-evaluation-remote-digital-care-platform/> The

© For personal and private use only. Reproduction must be permitted by the copyright holder. Email to copyright@mindbyte.eu.

full report is available on request.

Published on : Wed, 23 Mar 2022